These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 7728297)

  • 1. In-vitro effect of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors on non-hepatic LDL receptor activity: evidence of lack of stimulatory effect of pravastatin.
    Pedreño J; Sánchez JL; Zambón D; Ros E
    Coron Artery Dis; 1994 Dec; 5(12):971-7. PubMed ID: 7728297
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Abnormal regulation of the LDL-R and HMG CoA reductase genes in subjects with familial hypercholesterolemia with the "French Canadian mutation".
    Yu L; Qiu S; Genest J
    Atherosclerosis; 1996 Jul; 124(1):103-17. PubMed ID: 8800498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of different inhibitors of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, pravastatin sodium and simvastatin, on sterol synthesis and immunological functions in human lymphocytes in vitro.
    Kurakata S; Kada M; Shimada Y; Komai T; Nomoto K
    Immunopharmacology; 1996 Aug; 34(1):51-61. PubMed ID: 8880225
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pravastatin inhibited the cholesterol synthesis in human hepatoma cell line Hep G2 less than simvastatin and lovastatin, which is reflected in the upregulation of 3-hydroxy-3-methylglutaryl coenzyme A reductase and squalene synthase.
    Cohen LH; van Vliet A; Roodenburg L; Jansen LM; Griffioen M
    Biochem Pharmacol; 1993 Jun; 45(11):2203-8. PubMed ID: 8517861
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relative induction of mRNA for HMG CoA reductase and LDL receptor by five different HMG-CoA reductase inhibitors in cultured human cells.
    Morikawa S; Umetani M; Nakagawa S; Yamazaki H; Suganami H; Inoue K; Kitahara M; Hamakubo T; Kodama T; Saito Y
    J Atheroscler Thromb; 2000; 7(3):138-44. PubMed ID: 11480454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
    Lennernäs H; Fager G
    Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pravastatin: a new drug for the treatment of hypercholesterolemia.
    Jungnickel PW; Cantral KA; Maloley PA
    Clin Pharm; 1992 Aug; 11(8):677-89. PubMed ID: 1511541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of cyclosporine-inhibited low-density lipoprotein receptor activity in HepG2 cells by 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors.
    al Rayyes O; Wallmark A; Florén CH
    Hepatology; 1997 Apr; 25(4):991-4. PubMed ID: 9096609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Influence of pravastatin, a specific inhibitor of HMG-CoA reductase, on hepatic metabolism of cholesterol.
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    N Engl J Med; 1990 Jul; 323(4):224-8. PubMed ID: 2114543
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pravastatin inhibits cellular cholesterol synthesis and increases low density lipoprotein receptor activity in macrophages: in vitro and in vivo studies.
    Keidar S; Aviram M; Maor I; Oiknine J; Brook JG
    Br J Clin Pharmacol; 1994 Dec; 38(6):513-9. PubMed ID: 7888289
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of pravastatin in relation to low density lipoprotein receptor activity.
    Hayashi H; Naito C; Ito H; Kawamura M; Miyazaki S
    Curr Med Res Opin; 1990; 12(2):100-7. PubMed ID: 2118022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of propionic acid and pravastatin on HMG-CoA reductase activity in relation to forestomach lesions in the rat.
    Bueld JE; Bannenberg G; Netter KJ
    Pharmacol Toxicol; 1996 Apr; 78(4):229-34. PubMed ID: 8861780
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of pravastatin on hepatic cholesterol metabolism].
    Reihnér E; Rudling M; Ståhlberg D; Berglund L; Ewerth S; Björkhem I; Einarsson K; Angelin B
    Fortschr Med; 1991 Mar; 109(8):189-94. PubMed ID: 1905265
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The synergistic hypocholesterolemic activity of the potent cholesterol absorption inhibitor, ezetimibe, in combination with 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors in dogs.
    Davis HR; Pula KK; Alton KB; Burrier RE; Watkins RW
    Metabolism; 2001 Oct; 50(10):1234-41. PubMed ID: 11586500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The regulation of 3-hydroxy-3-methylglutaryl-CoA reductase activity, cholesterol esterification and the expression of low-density lipoprotein receptors in cultured monocyte-derived macrophages.
    Knight BL; Patel DD; Soutar AK
    Biochem J; 1983 Feb; 210(2):523-32. PubMed ID: 6305342
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of pravastatin on hepatic 3-hydroxy-3-methylglutaryl CoA reductase obtained from poloxamer 407-induced hyperlipidemic rats.
    Johnston TP; Palmer WK
    Pharmacotherapy; 1997; 17(2):342-7. PubMed ID: 9085326
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of single administration of pravastatin sodium on hepatic cholesterol metabolism in rats.
    Fujioka T; Tsujita Y
    Eur J Pharmacol; 1997 Apr; 323(2-3):223-8. PubMed ID: 9128842
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased in vitro oxidizability of low-density lipoprotein in hypercholesterolaemic patients treated with 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors.
    Kleinveld HA; Demacker PN; De Haan AF; Stalenhoef AF
    Eur J Clin Invest; 1993 May; 23(5):289-95. PubMed ID: 8354335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibitors of cholesterol biosynthesis increase hepatic low-density lipoprotein receptor protein degradation.
    Ness GC; Zhao Z; Lopez D
    Arch Biochem Biophys; 1996 Jan; 325(2):242-8. PubMed ID: 8561503
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The mechanism of lack of hypocholesterolemic effects of pravastatin sodium, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, in rats.
    Fujioka T; Nara F; Tsujita Y; Fukushige J; Fukami M; Kuroda M
    Biochim Biophys Acta; 1995 Jan; 1254(1):7-12. PubMed ID: 7811749
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.